Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007112 (prostatic adenocarcinoma)
 2,574 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Male CD2F1 mice bearing an MCAM-7 transplant in the right leg underwent surgical excision of the tumor and showed specific resistance to subsequent challenges with that identical tumor line. An in vivo response to tumor-specific antigens (MCAM-7 antigen) solubilized by hypertonic potassium chloride was measured by 24-hour footpad swelling response in male CD2F1 mice immunized to the tumor from which the antigens were extracted. These observations suggested that the transplantable MCAM-7 fibrosarcoma could produce immunity toward the solubilized MCAM-7 tumors antigens and that this tumor immunity could be measured by footpad swelling response to injection of the solubilized antigens, an indication of cell-mediated immunity. The footpad swelling response was also monitored in relation to the extent of tumor growth. Similar techniques have been applied to patients bearing adenocarcinoma of the prostate for whom skin testing was substituted for the measurement of footpad swelling in animals. Four of 10 patients, who had known prostate carcinoma and were given intradermal injections of soluble tumor antigens extracted from their tumors, exhibited a cutaneous, delayed type hypersensitivity response to the injected autologous tumor extracts. No positive reactions were observed in response to solubilized components of control tissues, including BPH. These observations suggest that some patients bearing adenocarcinoma of the prostate can exhibit an immunologic response to specific antigens present in their neoplasms.
 ...
PMID:Specificity of cell membrane antigens in prostate cancer. 8 64

Nb rat prostatic adenocarcinomas, previously induced by the administration of testosterone and estrogen, have been serially studied as heterotransplants into congenitally athymic (nude) mice and into groups of Nb rats. This animal system has been used to evaluate the chemotherapeutic efficacy of 5-fluorouracil and Ftorafur. The use of both species was to determine if there would be any significant difference in relative tumor growth in nude mice which lack functional T cells as opposed to intact Nb rats. The autonomous tumor, 102 Pr, is the subject of the thesis presented herein. One donor Nb rat bearing 102 Pr prostatic adenocarcinoma served as the donor for this experiment. The nude mice and Nb rats received the transplant on the same date and were subjected to the chemotherapies outlined above and were treated after there was sufficient increase in tumor volume from the 2 mm3 wedge to assure growth and neovascularity (greater than 60 mm3). Statistically significant data was presented revealing 5-fluorouracil to be efficacious in the treatment of these tumors. Also presented is data revealing differences in growth versus time in the respective recipient animal hosts. It is suggested herein that this combination animal model system could be used for screening potential cytotoxic chemotherapeutic agents.
 ...
PMID:Immunobiology and therapeutic manipulation of heterotransplanted Nb rat prostatic adenocarcinoma. Chemotherapy of autonomous tumor, 102 Pr, heterotransplanted into congenitally athymic (nude) mice and syngeneic Nb rats. 11 27

The Noble rat prostatic adenocarcinoma is an animal model which is used to study human prostatic carcinoma. It mimics the human condition in histology, in biochemistry with the production of acid phosphatase, and in tumor growth which is relatively constant. Additionally, it is hormonally dependent and metastasizes. This animal model should provide an avenue for the evaluation of cytotoxic chemotherapeutic agents heretofore receiving little attention from the urologic community.
 ...
PMID:The Nb rat: prostatic adenocarcinoma model. 42 31

The Nb rat prostatic adenocarcinoma is a well-characterized, hormonally induced family of tumors that are all readily transplantable into congenitally athymic (nude) mice. Because of this versatile heterotransplantation model, multiple replicate copies of individual tumors can be studied "in rodent." We have extended this by studying the chemotherapeutic response of such tumors and believe that this provides a useful avenue for evaluation of cytotoxic agents. Indeed, this combination of both animal model systems may provide a useful experimental tool to evaluate tumor growth, histopathologic changes and responsiveness to appropriate therapy. We report herein that two Nb rat prostatic carcinomas (2 Pr-129-D-11A and Pr-90) and thie responsiveness to Adriamycin and 5-fluorouracil are objective by studying both growth rates and tumor histology.
 ...
PMID:The effect of 5-fluorouracil and adriamycin on heterotransplantation of Noble rat prostatic tumors in congenitally athymic (nude) mice. 47 60

Mice bearing a 3-methylcholanthrene-induced fibrosarcoma (MCAM-7) transplant in the right leg underwent surgical excision of the tumor and showed specific resistance to subsequent challenges with that identical tumor line. An in vivo response to tumor-specific antigens (MCAM-7 antigen) solubilized by hypertonic potassium chloride was measured by 24-hour footpad swelling response in mice immunized to the tumor from which the antigens were extracted. These observations suggested that the transplantable MCAM-7 fibrosarcoma could produce immunity toward the solubilized MCAM-7 tumor antigens and that this tumor immunity could be measured by footpad swelling response to injection of the solubilized antigens, an indication of cell-mediated immunity. The footpad swelling response was also minotored in relation to the extent of tumor growth. Mice received MCAM-7 tumor transplants by injection of 5 times 10-6 tumor cells and were tested for footpad swelling response at intervals following tumor transfer. A significant footpad response to injected MCAM-7 antigens was present 10 days following tumor transfer; at this time signs of tumor growth were only minimally detectable. The footpad swelling response to injected antigens disappeared by 28 days following initial tumor transfer; at this time the tumor diameters were in excess of 1.0 cm. Surgical removal of tumor at this point promptly restored footpad responses within 24 hours. Similar techniques have been applied to patients bearing adenocarcinoma of the prostate, where skin testing was substituted for the measurement of footpad swelling in animals. Seven patients with known prostatic carcinoma were given intradermal injections of soluble tumor antigens extracted from their own tumors. Three of the seven patients exhibited a cutaneous delayed type hypersensitivity response to the injected autologous tumor extracts. No positivereactions were observed in response to solubilized components of control tissues, including benign prostatic hyperplasia. The significance of the demonstrated concomitant immunity in these patients has not been resolved. However, these observations suggest that some patients bearing adenocarcinoma of the prostate can exhibit an immunologic response to specific antigens present in their own neoplasms.
 ...
PMID:Specificity of cell membrane antigens in prostatic cancer. 113 99

Copenhagen x Fisher F1 rats were implanted with the androgen-dependent Dunning R3327 prostatic adenocarcinoma. When the tumors had median volumes of ca 470 mm3, the rats were castrated and/or treated with 6-methylene-4-pregnene-3,20-dione (6MP) in different doses. Tumor growth inhibition occurred in all castrated and treated groups, with decrease in volume of the epithelial compartment in the intact group. Tumor volumes at the highest dose level of 6MP equalled those observed in the castrate group. Plasma levels of testosterone were within the normal range. The administration of 6MP surprisingly induced an increment of tumor blood flow in the castrate group. Also in castrated and testosterone-supplemented animals, 6MP induced a reduction of prostatic tumor growth. Through the castration-like effect on tumor growth, the use of 6MP may represent an attractive alternative to castration for treatment of androgen-responsive prostate cancer.
 ...
PMID:Effects of 6-methylene progesterone on growth, morphology, and blood flow of the Dunning R3327 prostatic adenocarcinoma. 157 66

This study was designed to investigate whether the combination of castration with estrogen treatment for 6 weeks (combined treatment) further inhibits growth of the Dunning R3327 rat prostatic adenocarcinoma as compared with castration alone. Combined treatment arrested tumor growth more effectively than castration. Combined treatment also induced morphological changes in both tumor stroma and epithelium that were not found in tumors from castrated animals. The volume density of the tumor epithelium was reduced and the volume density of the tumor stroma was increased by the combined treatment as compared with castration alone. The number of tumor epithelial cells was calculated by morphological methods: combined treatment lowered the number as compared with castration alone. The number of tumor epithelial cells was similar in castrated and intact rats. Both combined treatment and castration alone reduced tumor epithelium cell size as compared with tumors from intact rats. These findings suggest that estrogen may have direct effects on total number and function of prostatic tumor cells.
 ...
PMID:Estrogen treatment combined with castration inhibits tumor growth more effectively than castration alone in the Dunning R3327 rat prostatic adenocarcinoma. 169 14

LY181984 is a compound in a series of orally active diarylsulfonylureas with broad spectrum in vivo activity against syngeneic rodent and human xenograft tumor models. The PAIII rat prostatic adenocarcinoma model was used to evaluate the effects of this antitumor agent on the lymphatic and pulmonary metastasis of the tumor in male Lobund Wistar rats. LY181984 was inactive against the proliferation of PAIII cells in vitro. Following subcutaneous implantation of 10(6) PAIII cells in the tail, oral administration of LY181984 (25.0, 50.0, or 100.0 mg./kg./day) for 30 days had no significant effects on body weight gain. LY181984 treatment produced significant (p less than 0.05) dose-dependent inhibition of primary tumor growth in the tail (max. inhibition = 46% from untreated control levels). In these same animals, LY181984 administration produced significant (p less than 0.05) dose-dependent inhibiton of PAIII metastasis from the primary tumor in the tail to the gluteal and iliac lymph nodes (maximal responses = 79% and 80% from control values, respectively). PAIII metastasis to the lungs was significantly inhibited by oral LY181984 treatment. Numbers of pulmonary foci in PAIII-bearing rats were significantly (p less than 0.05) reduced by LY181984 administration in a dose-dependent manner (maximal reduction = 78% from control values). While the non-toxic doses (less than 100.0 mg./kg./day for 28 days) of LY181984 produced marked decreases in tumor growth and metastasis, administration of the compound had no effect on the survival of PAIII-bearing rats. These data support the contention that LY181984 represents a new class of orally active antitumor and antimetastatic agents with potential efficacy in the treatment of hormone-insensitive prostatic cancer. Further studies are needed to define maximal efficacy of LY181984 and other sulfonylurea agents in urogenital solid tumor animal models.
 ...
PMID:Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984. 173 31

The combination of inhibitors of ornithine decarboxylase and polyamine oxidase, and of antibiotics suitable for the (partial) decontamination of the gastrointestinal tract, with a polyamine deficient diet, is responsible for the almost complete inhibition of the growth of MAT-LyLu prostatic adenocarcinoma. In the tumor-bearing animals, erythrocyte spermidine levels were reduced, but spermine concentrations were increased. As has been previously observed, the increase in erythrocyte spermine level was associated with an enhancement of malignant cell death. Adriamycin administration did neither diminish tumor growth, nor potentiate the antitumor effect of polyamine deprivation treatment. Interruption of the polyamine deprivation treatment was accompanied by a significant enhancement of tumor growth. Since polyamine deprivation causes only reversible growth inhibition, it seems not appropriate as a monotherapy.
 ...
PMID:The growth of MAT-LyLu rat prostatic adenocarcinoma can be prevented in vivo by polyamine deprivation. 194 11

The object of the present investigations was delineation of the exclusive effects of cyclophosphamide (Cytoxan) on host humoral response to tumor, as evaluated by the level of circulating antigen/antibody complexes (AACs), which may reflect the chemo-responsiveness of hosts and provide a rationale for new therapeutic strategies. Our data, recorded in Copenhagen X Fischer rats bearing Dunning's R-3327 Mat Ly-Lu adenocarcinoma of the prostate, show no modulatory effect of cyclophosphamide at 10 mg/kg, a nonspecific immunosuppressive effect at 30 mg/kg, and a definite immunostimulatory effect on host humoral immunity at 100 mg/kg. Sequential determination of AAC levels at different stages of tumor growth, i.e. from the primary to the metastatic stage, performed with the original purpose of demonstrating that any disturbance in the immunoregulatory mechanism of the host was due to cyclophosphamide rather than to changes in tumor load, revealed that levels of AACs parallel disease progression in the initial stages of primary tumor growth but rapidly decrease to near-normal levels in the presence of heavy tumor burden.
 ...
PMID:Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate. 202 60


1 2 3 4 5 6 7 Next >>